Maternal Use of Integrase Strand Transfer Inhibitors During Pregnancy and Infant Neurodevelopment

Do integrase strand transfer inhibitors (INSTIs) used as part of antiretroviral treatment (ART) by pregnant women with HIV have an adverse association with their infant’s neurodevelopment?In this cohort study of 1006 children aged 1 year born to women with HIV, assessments of cognition, language, and motor development yielded no clinically meaningful differences between those exposed in utero to INSTI-based ART regimens and other types of ART regimens. Mean scores were close to the standard population mean of 100 within each ART exposure group.These findings support current recommendations to include INSTI-based regimens as part of first-line treatment for pregnant women with HIV.

Corresponding Author: Paige L. Williams, PhD, Department of Biostatistics, Harvard T. H. Chan School of Public Health, 677 Huntington Ave, Boston, MA 02445 (paige@hsph.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.